Session

Patient outcomes in IBD trials

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH
PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

THE IMPACT OF GROUP COGNITIVE BEHAVIORAL THERAPY ON IBD PATIENTS’ PSYCHOSOCIAL FUNCTIONING, INFLAMMATION AND DISEASE SEVERITY INDICES: A RANDOMIZED CONTROLLED STUDY
THE IMPACT OF GROUP COGNITIVE BEHAVIORAL THERAPY ON IBD PATIENTS’ PSYCHOSOCIAL FUNCTIONING, INFLAMMATION AND DISEASE SEVERITY INDICES: A RANDOMIZED CONTROLLED STUDY

MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS
SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Patient outcomes in IBD trials  et al.

SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS
SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN IN CROHN’S DISEASE OPTIMISES ANTI-TNF PHARMACOKINETICS

Patient outcomes in IBD trials  et al.

THE IMPACT OF GROUP COGNITIVE BEHAVIORAL THERAPY ON IBD PATIENTS’ PSYCHOSOCIAL FUNCTIONING, INFLAMMATION AND DISEASE SEVERITY INDICES: A RANDOMIZED CONTROLLED STUDY
THE IMPACT OF GROUP COGNITIVE BEHAVIORAL THERAPY ON IBD PATIENTS’ PSYCHOSOCIAL FUNCTIONING, INFLAMMATION AND DISEASE SEVERITY INDICES: A RANDOMIZED CONTROLLED STUDY

Patient outcomes in IBD trials  et al.

MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Patient outcomes in IBD trials  et al.

PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH
PATIENTS WITH ULCERATIVE COLITIS REPORT IMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY, AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT IN TWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH

Patient outcomes in IBD trials  et al.

Item 1 - 10 / 10
1